Lhermitte Sign After Chemo-IMRT of Head-and-Neck Cancer: Incidence, Doses, and Potential Mechanisms
- 1. Department of Radiation Oncology, University of Michigan, Ann Arbor, MI (United States)
Description
Purpose: We have observed a higher rate of Lhermitte sign (LS) after chemo–intensity-modulated radiotherapy (IMRT) of head-and-neck cancer than the published rates after conventional radiotherapy. We hypothesized that the inhomogeneous spinal cord dose distributions produced by IMRT caused a "bath-and-shower" effect, characterized by low doses in the vicinity of high doses, reducing spinal cord tolerance. Methods and Materials: Seventy-three patients with squamous cell carcinoma of the oropharynx participated in a prospective study of IMRT concurrent with weekly carboplatin and paclitaxel. Of these, 15 (21%) reported LS during at least 2 consecutive follow-up visits. Mean dose, maximum dose, and partial volume and absolute volume (in milliliters) of spinal cord receiving specified doses (≥10 Gy, ≥20 Gy, ≥30 Gy, and ≥40 Gy), as well as the pattern of dose distributions at the "anatomic" spinal cord (from the base of the skull to the aortic arch) and "plan-related" spinal cord (from the top through the bottom of the planning target volumes), were compared between LS patients and 34 non-LS patients. Results: LS patients had significantly higher spinal cord mean doses, V30, V40, and absolute volumes receiving 30 Gy or more and 40 Gy or more compared with the non-LS patients (p < 0.05). The strongest predictors of LS were higher V40 and higher cord volumes receiving 40 Gy or more (p ≤ 0.007). There was no evidence of larger spinal cord volumes receiving low doses in the vicinity of higher doses (bath-and-shower effect) in LS compared with non-LS patients. Conclusions: Greater mean dose, V30, V40, and cord volumes receiving 30 Gy or more and 40 Gy or more characterized LS compared with non-LS patients. Bath-and-shower effects could not be validated in this study as a potential contributor to LS. The higher-than-expected rates of LS may be because of the specific concurrent chemotherapy agents or more accurate identification of LS in the setting of a prospective study.
Availability note (English)
Available from http://dx.doi.org/10.1016/j.ijrobp.2011.10.052Additional details
Identifiers
- DOI
- 10.1016/j.ijrobp.2011.10.052;
- PII
- S0360-3016(11)03460-2;
Publishing Information
- Journal Title
- International Journal of Radiation Oncology, Biology and Physics
- Journal Volume
- 83
- Journal Issue
- 5
- Journal Page Range
- p. 1528-1533
- ISSN
- 0360-3016
- CODEN
- IOBPD3
INIS
- Country of Publication
- United States
- Country of Input or Organization
- International Atomic Energy Agency (IAEA)
- INIS RN
- 44104075
- Subject category
- S62: RADIOLOGY AND NUCLEAR MEDICINE;
- Descriptors DEI
- CARCINOMAS; CHEMOTHERAPY; HEAD; NECK; PATIENTS; PLANNING; RADIATION DOSE DISTRIBUTIONS; RADIATION DOSES; RADIOTHERAPY; SKULL; SPINAL CORD; TOLERANCE
- Descriptors DEC
- BODY; CENTRAL NERVOUS SYSTEM; DISEASES; DOSES; MEDICINE; NEOPLASMS; NERVOUS SYSTEM; NUCLEAR MEDICINE; ORGANS; RADIOLOGY; SKELETON; THERAPY
Optional Information
- Copyright
- Copyright (c) 2012 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved.